Role of microparticles in dengue virus infection and its impact on medical intervention strategies

Yale Journal of Biology and Medicine

Volumn 85, Issue 1, 2012, Pages 3-18

  Clark, Kristina Bargeron ^a   Hsiao, Hui Mien ^a   Noisakran, Sansanee ^a,b   Tsai, Jih Jin ^c,d   Perng, Guey Chuen ^a,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Aedes mosquitoes; Alternative virion; Dengue virus; Microparticles; Vaccine; Vector borne transmission

Indexed keywords

DENGUE VACCINE; VIRUS HEMAGGLUTININ;

AEDES; ARTICLE; CELL LINE; DENGUE; DENGUE VIRUS; DISEASE CARRIER; DISEASE MODEL; DRUG DESIGN; GENE DOSAGE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MICROSCOPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); ULTRASTRUCTURAL MICROSCOPY; VIREMIA; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; CELL-DERIVED MICROPARTICLES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE VECTORS; DRUG DESIGN; HUMANS;

DENGUE VIRUS;

EID: 84859296706     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (142)

1. NIAID. Dengue Fever [Internet]. 2005 April. Available from: http://www.niaid.nih.gov/factsheets/dengue.htm.
2. WHO. Dengue guidelines for diagnosis, treatment, prevention and control. World Health Organization [Internet]. 2009: Available from: http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf.
3. Kurane I, Kontny U, Janus J, Ennis FA. Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infections. Arch Virol. 1990;110(1-2):91-101.
4. Azizan A, Fitzpatrick K, Signarovitz A, Tanner R, Hernandez H, Stark L, et al. Profile of time-dependent VEGF upregulation in human pulmonary endothelial cells, HPMEC-ST1.6R infected with DENV-1, -2,-3, and -4 viruses. Virol J. 2009;6(1):49.
5. Cabello-Gutierrez C, Manjarrez-Zavala ME, Huerta-Zepeda A, Cime-Castillo J, Monroy-Martinez V, Correa BB, et al. Modification of the cytoprotective protein C pathway during Dengue virus infection of human endothelial vascular cells. Thromb Haemost. 2009;101(5):916-28.
6. Arevalo MT, Simpson-Haidaris PJ, Kou Z, Schlesinger JJ, Jin X. Primary human endothelial cells support direct but not antibody-dependent enhancement of dengue viral infection. J Med Virol. 2009;81(3):519-28.
7. Theofilopoulos AN, Brandt WE, Russell PK, Dixon FT. Replication of dengue-2 virus in cultured human lymphoblastoid cells and subpopulations of human peripheral leukocytes. J Immunol. 1976;117(3):953-61.
8. Sriurairatna S, Bhamarapravati N, Diwan AR, Halstead SB. Ultrastructural studies on dengue virus infection of human lymphoblasts. Infect Immunol. 1978;20(1):173-9.
9. Andrews BS, Theofilopoulos AN, Peters CJ, Loskutoff DJ, Brandt WE, Dixon FJ. Replication of dengue and junin viruses in cultured rabbit and human endothelial cells. Infect Immunol. 1978;20(3):776-81.
10. Kurane I, Ennis FA. Production of interferon alpha by dengue virus-infected human monocytes. J Gen Virol. 1988;69(Pt 2):445-9.
11. Kurane I, Hebblewaite D, Brandt WE, Ennis FA. Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody- dependent cell-mediated cytotoxicity. J Virol. 1984;52(1):223-30.
12. Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, Liu S, et al. Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology. 2011;410(1):240-7.
13. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265(5596):739-41.
14. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, et al. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol. 2007;81(24):13325-34.
15. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, et al. The dual-specific binding of dengue virus and target cells for the antibody- dependent enhancement of dengue virus infection. J Immunol. 2006;176(5):2825-32.
16. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989;40(4):444-51.
17. Hase T, Summers PL, Eckels KH. Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes. Arch Virol. 1989;104(1-2):129-43.
18. Espina LM, Valero NJ, Hernandez JM, Mosquera JA. Increased apoptosis and expression of tumor necrosis factor-alpha caused by infection of cultured human monocytes with dengue virus. Am J Trop Med Hyg. 2003;68(1):48-53.
19. Mosquera JA, Hernandez JP, Valero N, Espina LM, Anez GJ. Ultrastructural studies on dengue virus type 2 infection of cultured human monocytes. Virol J. 2005;2:26.
20. Honda S, Saito M, Dimaano EM, Morales PA, Alonzo MT, Suarez LA, et al. Increased phagocytosis of platelets from patients with secondary Dengue virus infection by human macrophages. Am J Trop Med Hyg. 2009;80(5):841-5.
21. Marianneau P, Steffan AM, Royer C, Drouet MT, Jaeck D, Kirn A, et al. Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol. 1999;73(6):5201-6.
22. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA, et al. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood. 2010;115(9):1823-34.
23. Hober D, Nguyen TL, Shen L, Ha DQ, Huong VT, Benyoucef S, et al. Tumor necrosis factor alpha levels in plasma and wholeblood culture in dengue-infected patients: relationship between virus detection and preexisting specific antibodies. J Med Virol. 1998;54(3):210-8.
24. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108(5):717-25.
25. Gubler DJ, Kuno G, editors. Dengue And Dengue Hemorrhagic Fever. 1st edition. Wallingford, UK: CABI; 1997.
26. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 1990;44:649-88.
27. Stadler K, Allison SL, Schalich J, Heinz FX. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997;71(11):8475-81.
28. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev. 1990;3(4):376-96.
29. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427(6972):313-9.
30. Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, Modis Y. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol. 2009;83(9):4338-44.
31. Plevka P, Battisti AJ, Junjhon J, Winkler DC, Holdaway HA, Keelapang P, et al. Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres. EMBO Rep. 2011;12(6):602-6.
32. Mondotte JA, Lozach PY, Amara A, Gamarnik AV. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J Virol. 2007;81(13):7136-48.
33. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol. 2000;74(17):7814-23.
34. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008;15(3):312-7.
35. Hase T, Summers PL, Eckels KH, Baze WB. An electron and immunoelectron microscopic study of dengue-2 virus infection of cultured mosquito cells: maturation events. Arch Virol. 1987;92(3-4):273-91.
36. Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CK, Walther P, et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe. 2009;5(4):365-75.
37. Cardiff RD, Russ SB, Brandt WE, Russell PK. Cytological localization of Dengue-2 antigens: an immunological study with ultrastructural correlation. Infect Immunol. 1973;7(5):809-16.
38. Barth OM. Replication of dengue viruses in mosquito cell cultures?a model from ultrastructural observations. Mem Inst Oswaldo Cruz. 1992;87(4):565-74.
39. Barth OM, Cortes LM, Lampe E, Farias Filho JC. Ultrastructural aspects of virus replication in one fatal case and several other isolates from a dengue type 2 outbreak in Rio de Janeiro. Mem Inst Oswaldo Cruz. 1994;89(1):21-4.
40. Smith TJ, Brandt WE, Swanson JL, McCown JM, Buescher EL. Physical and biological properties of dengue-2 virus and associated antigens. J Virol. 1970;5(4):524-32.
41. Sriurairatna S, Bhamarapravati N, Phalavadhtana O. Dengue virus infection of mice: morphology and morphogenesis of dengue type-2 virus in suckling mouse neurones. Infect Immunol. 1973;8(6):1017-28.
42. Stevens TM, Schlesinger RW. Studies on the nature of dengue viruses. I. Correlation of particle density, infectivity, and RNA content of type 2 virus. Virology. 1965;27(1):103-12.
43. Brandt WE, Cardiff RD, Russell PK. Dengue virions and antigens in brain and serum of infected mice. J Virol. 1970;6(4):500-6.
44. Brandt WE, Chiewslip D, Harris DL, Russell PK. Partial purification and characterization of a dengue virus soluble complement-fixing antigen. J Immunol. 1970;105(6):1565-8.
45. Sabin AB, Schlesinger RW. Production of Immunity to Dengue with Virus Modified by Propagation in Mice. Science. 1945;101(2634):640-2.
46. Kimura R, Hotta S. Studies on dengue fever (VI). On the inoculation of dengue virus into mice (in Japanese). Nippom Igaku. 1944;(3379):629-33.
47. Junjhon J, Lausumpao M, Supasa S, Noisakran S, Songjaeng A, Saraithong P, et al. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J Virol. 2008;82(21):10776-91.
48. Offit PA. Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases. 1st edition. New York: HarperCollins; 2007.
49. Boriskin Yu S, Kaptsova TI, Lotte VD, Skvortsova OI, Orvell C. Laboratory markers for over-attenuation of mumps vaccine virus. Vaccine. 1988;6(6):483-8.
50. Pattnaik P, Babu JP, Verma SK, Tak V, Rao PV. Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846(1-2):184-94.
51. Talarico LB, Damonte EB. Interference in dengue virus adsorption and uncoating by carrageenans. Virology. 2007;363(2):473-85.
52. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997;3(8):866-71.
53. Anez G, Men R, Eckels KH, Lai CJ. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J Virol. 2009;83(20):10384-94.
54. Perera R, Khaliq M, Kuhn RJ. Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res. 2008;80(1):11-22.
55. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103-13.
56. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328(5979):745-8.
57. Noisakran S, Onlamoon N, Hsiao HM, Clark KB, Villinger F, Ansari AA, et al. Infection of Bone Marrow Cells by Dengue Virus In Vivo. Exp Hematol. 2011 Dec 19. [Epub ahead of print]
58. Noisakran S, Gibbons RV, Songprakhon P, Jairungsri A, Ajariyakhajorn C, Nisalak A, et al. Detection of dengue virus in platelets isolated from dengue patients. Southeast Asian J Trop Med Public Health. 2009;40(2):253-62.
59. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11(3):480-96.
60. Sabin AB. Electron microscope studies on human dengue serum. Amer J Publ Health. 1951;41:1215.
61. Noisakran S, Chokephaibulkit K, Songprakhon P, Onlamoon N, Hsiao HM, Villinger F, et al. A re-evaluation of the mechanisms leading to dengue hemorrhagic fever. Ann NY Acad Sci. 2009;1171(Suppl 1):E24-35.
62. Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, et al. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med. 2011;236(5):515-23.
63. Aliotta JM, Pereira M, Johnson KW, de Paz N, Dooner MS, Puente N, et al. Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Exp Hematol. 2010;38(3):233-45.
64. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78(9):838-48.
65. Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z. Emission of membrane vesicles: roles in complement resistance, immunity and cancer. Springer Semin Immunopathol. 2005;27(3):375-87.
66. Jin M, Drwal G, Bourgeois T, Saltz J, Wu HM. Distinct proteome features of plasma microparticles. Proteomics. 2005;5(7):1940-52.
67. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-9.
68. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20(9):1487-95.
69. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30(2):111-42.
70. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda). 2005;20:22-7.
71. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle- mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1(1):98-110.
72. Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol. 2007;137(1):36-48.
73. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9(8):581-93.
74. Holmgren L, Szeles A, Rajnavolgyi E, Folkman J, Klein G, Ernberg I, et al. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood. 1999;93(11):3956-63.
75. Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, et al. Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol. 2004;34(10):2834-42.
76. Esser MT, Graham DR, Coren LV, Trubey CM, Bess JW Jr., Arthur LO, et al. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol. 2001;75(13):6173-82.
77. Soler N, Marguet E, Verbavatz JM, Forterre P. Virus-like vesicles and extracellular DNA produced by hyperthermophilic archaea of the order Thermococcales. Res Microbiol. 2008;159(5):390-9.
78. Meckes DG Jr., Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA. 2010;107(47):20370-5.
79. Schaar V, Nordstrom T, Morgelin M, Riesbeck K. Moraxella catarrhalis outer membrane vesicles carry beta-lactamase and promote survival of Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin. Antimicrob Agents Chemother. 2011;55(8):3845-53.
80. Calistri A, Salata C, Parolin C, Palu G. Role of multivesicular bodies and their components in the egress of enveloped RNA viruses. Rev Med Virol. 2009;19(1):31-45.
81. Quesenberry PJ, Dooner MS, Aliotta JM. Stem cell plasticity revisited: the continuum marrow model and phenotypic changes mediated by microvesicles. Exp Hematol. 2010;38(7):581-92.
82. Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol. 2000;165(3):1259-65.
83. Leroyer AS, Rautou PE, Silvestre JS, Castier Y, Leseche G, Devue C, et al. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol. 2008;52(16):1302-11.
84. Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis. J Intern Med. 2008;263(5):528-37.
85. Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, et al Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68(16):2667-88.
86. Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines. 2011;10(5):575-88.
87. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al. Platelets amplify inflammation in arthritis via collagen- dependent microparticle production. Science. 2010;327(5965):580-3.
88. Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum. 2005;52(11):3337-48.
89. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13(3):269-88.
90. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood. 2011;118(7):1903-11.
91. Sadallah S, Eken C, Martin PJ, Schifferli JA. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. J Immunol. 2011;186(11):6543-52.
92. Schwertz H, Koster S, Kahr WH, Michetti N, Kraemer BF, Weitz DA, et al. Anucleate platelets generate progeny. Blood. 2010;115(18):3801-9.
93. Halstead SB, O'Rourke EJ, Allison AC. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med. 1977;146(1):218-29.
94. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2-9.
95. Zucker JR. Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Emerg Infect Dis. 1996;2(1):37-43.
96. Janzen HG, Rhodes AJ, Doane FW. Chikungunya virus in salivary glands of Aedes aegypti (L.): an electron microscope study. Can J Microbiol. 1970;16(7):581-6.
97. Phillips A, Mossel E, Sanchez-Vargas I, Foy B, Olson K. Alphavirus transducing system: tools for visualizing infection in mosquito vectors. J Vis Exp. 2010;(45).
98. WHO. Dengue Vaccine Development: The role of the WHO South-East Asia Regional Office. 2010.
99. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29:587-619.
100. Thomas SJ. The necessity and quandaries of dengue vaccine development. J Infect Dis. 2011;203(3):299-303.
101. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis. 2009;9(11):678-87.
102. Thomas SJ, Endy TP. Vaccines for the prevention of dengue: Development update. Hum Vaccin. 2011;7(6):674-84.
103. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011;85(4):724-31.
104. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis. 2011;24(5):442-50.
105. Moxon ER, Siegrist CA. The next decade of vaccines: societal and scientific challenges. Lancet. 2011;378(9788):348-59.
106. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg. 2009;81(5):825-33.
107. Gusman MG. Dengue vaccines: new developments. Drugs Future. 2011;36:45-62.
108. Simmons JS, St. John JH, Reynolds FHK. Experimental studies of dengue. Philippine J Sci. 1931;44:1-251.
109. Rudnick A, Lim TW, editors. Dengue Fever Studies in Malaysia. Kuala Lumpur: The Institute for Medical Research; 1986.
110. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1:30-50.
111. Hotta S. Experimental studies on dengue I isolation, identification and modification of the virus. J Infect Dis. 1952;90:1-9.
112. Mota J, Rico-Hesse R. Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS One. 2011;6(6):e20762.
113. Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol. 2009;83(17):8638-45.
114. Kuruvilla JG, Troyer RM, Devi S, Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAGhu) mice. Virology. 2007;369(1):143-52.
115. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis. 1973;128(1):7-14.
116. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg. 2009;80(2):302-11.
117. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg. 2008;78(3):426-33.
118. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis. 1997;176(2):322-30.
119. Perng GC, Lei HY, Lin YS, Chokephaibulkit K. Dengue Vaccines: Challenge and Confrontation. World Journal of Vaccines. 2011;1(4):109-30.
120. Bierman HR, Nelson ER. Hematodepressive Virus Diseases of Thailand. Ann Intern Med. 1965;62:867-84.
121. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med. 2003;197(7):823-9.
122. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol. 2008;82(8):3939-51.
123. Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, et al. Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology. 2009;383(2):207-15.
124. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol. 2011;85(13):6548-56.
125. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, et al. Inhibition of dengue virus by targeting viral NS4B protein. J Virol. 2011;85(21):11183-95.
126. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 2007;195(5):665-74.
127. Nakao S, Lai CJ, Young NS. Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. Blood. 1989;74(4):1235-40.
128. Tsai J-J, Liu L-T, Chang K, Wang S-H, Hsiao H-M, Clark KB, et al. The importance of hematopoietic progenitor cells in dengue. Therapeutic Advances in Hematology. 2011 Sept 5 [Epub ahead of print]
129. Halstead SB. Dengue. Lancet. 2007;370(9599):1644-52.
130. Marchette NJ, Halstead SB, Falkler WA Jr., Stenhouse A, Nash D. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis. 1973;128(1):23-30.
131. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis. 2006;19(5):429-36.
132. Chen JP, Cosgriff TM. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis. 2000;11(5):461-83.
133. Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Immunopathogenesis of dengue virus infection. J Biomed Sci. 2001;8(5):377-88.
134. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis. 2002;6(2):118-24.
135. Iyngkaran N, Yadav M, Sinniah M. Augmented inflammatory cytokines in primary dengue infection progressing to shock. Singapore Med J. 1995;36(2):218-21.
136. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis. 1999;179(4):755-62.
137. Gagnon SJ, Mori M, Kurane I, Green S, Vaughn DW, Kalayanarooj S, et al. Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. J Med Virol. 2002;67(1):41-6.
138. Liu CC, Huang KJ, Lin YS, Yeh TM, Liu HS, Lei HY. Transient CD4/CD8 ratio inversion and aberrant immune activation during dengue virus infection. J Med Virol. 2002;68(2):241-52.
139. Suharti C, van Gorp EC, Dolmans WM, Setiati TE, Hack CE, Djokomoeljanto R, et al. Cytokine patterns during dengue shock syndrome. Eur Cytokine Netw. 2003;14(3):172-7.
140. Tsai JJ, Jen YH, Chang JS, Hsiao HM, Noisakran S, Perng GC. Frequency alterations in key innate immune cell components in the peripheral blood of dengue patients detected by FACS analysis. J Innate Immun. 2011;3(5):530-40.
141. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397-405.
142. Deeks SG. Protease inhibitors as immunomodulatory drugs for HIV infection. Clin Pharmacol Ther. 2007;82(3):248-50.